Pharma

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, recently performed the first cataract surgery in the country using Dexycu (EyePoint Pharmaceuticals), administered as a…

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make…

Nicox SA has taken several steps in the past few months to increase shareholder value. It has two product candidates headed toward Phase II trials,…

Before he was chairman of Oyster Point Pharmaceuticals, Michael Ackermann, PhD, worked with a team developing an implantable device. It looked promising, but it was…

At OIS@AAO 2018, strong attendance at the breakfast breakout session “Evolution of the Dry Eye Market” made a statement about the current level of interest…

Few therapeutic areas in medicine have a drug pipeline as flush as retina’s, as shown by trial results of a dozen or more emerging therapies…

The steroidal implant YUTIQ for treatment of chronic, noninfectious posterior uveitis is the second drug in EyePoint Pharmaceuticals’ ophthalmology portfolio to receive Food and Drug…

In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to…

Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’…

Last week, one day before the American Society of Retina Specialists and OIS Retina convened in Vancouver, Allergan and its collaborative partner Molecular Partners touted…

When Ocular Therapeutix resubmitted its new drug application for Dextenza late in June, it represented a milestone in the company’s effort to essentially reshape itself…